Fig. 1 · Structure

Documents & Downloads

Axitinib

Cat. No. A10103 CAS 319460-85-0

VEGFR inhibitor

Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).

In Stock

Publications for Axitinib

5 publications citing this product

  1. Sophie J. Bakri, .et al. , PLoS One, 2024, 19(6): e0304782 PMID: 38833447
  2. Hongwan Ding, .et al. , Toxicol Appl Pharmacol, 2024, May:486:116950 PMID: 38701902
  3. Hongwan Ding, .et al. , Research Square, 2023, Dec 28
  4. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  5. Youcef M. Rustum, .et al. , Int J Mol Sci, 2018, Nov; 19(11): 3378 PMID: 30380599

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Axitinib binds an inactive VEGFR2 conformation. In a co-crystal containing the kinase and juxtamembrane domains, VEGFR2 adopted DFG-out/JM-in geometry, with the axitinib amide methyl group contacting I804 at 3.8 Å. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
VEGFR1/FLT1 IC50 0.1nM
VEGFR2/Flk1 IC50 0.18nM
VEGFR2/KDR IC50 0.2nM
VEGFR3 IC50 0.1nM-0.3nM
PDGFRβ IC50 1.6nM
Kit IC50 1.7nM
PDGFRα IC50 5.0nM
CSF-1R IC50 73nM
FLT3 IC50 >1μM

9 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
518A2 IC50 4.4 μM Cytotoxicity against human 518A2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay [PMID: 31958738]
A549 IC50 > 25 μM Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay [PMID: 30562697]
A549 IC50 22.4 μM Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay [PMID: 30108994]
A549 IC50 4.88 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 31445229]
BaF3 GI50 0.002 μM Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.005 μM Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.007 μM Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.012 μM Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.013 μM Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.014 μM Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.105 μM Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.108 μM Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.11 μM Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]
BaF3 GI50 0.12 μM Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]
BaF3 GI50 0.129 μM Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.156 μM Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 0.2 μM Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]
BaF3 GI50 0.24 μM Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]
BaF3 GI50 0.35 μM Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]

19 records · Scroll to view more

Axitinib Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Axitinib from 2 published references. In vitro models include human umbilical vein endothelial cells (HUVECs), passage <6. In vivo models include PC-3 human prostate carcinoma xenografts in male NCr nu/nu mice.

Axitinib In Vitro Studies

In HUVECs, axitinib inhibited VEGF-induced VEGFR2 autophosphorylation with an IC50 of 0.013 nM. Cells received compound for 1 h before a 5-min VEGF stimulus. This assay-specific IC50 is an endpoint measurement, not a recommended working concentration. [1]

VEGFR2 binding conformation

Biochemical assay · Nonphosphorylated VEGFR2 catalytic and juxtamembrane domains (plus-JM construct). [1]

The axitinib complex showed an inactive DFG-out conformation with the juxtamembrane segment folded into the regulatory pocket (JM-in).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Contact between the axitinib amide methyl group and VEGFR2 I804Structural distance 3.8 Å[1]
VEGFR2 conformation in the axitinib complexBinding conformation DFG-out / JM-in[1]

Literature-Reported Treatment Conditions

Method
Axitinib–VEGFR2 co-crystal analysis.
Reported limits
Compound concentration used for complex preparation is not stated in the inspected main-text section; no assay dosing recommendation is inferred.
Methods and source locations

Compound reported in the paper: Axitinib; Compound label in the paper: AG-013736

Compound-level published research; no batch equivalence or Adooq validation claimed.

Results: Crystal Structures Reveal Distinct JM Conformations; Figures 1A and 2C; Methods: Crystal Structure Determinations; data deposition 4AGC

Contact between the axitinib amide methyl group and VEGFR2 I804: X-ray crystallographic complex analysis; distance reported in Results text. — Results: Crystal Structures Reveal Distinct JM Conformations, paragraph discussing Figure 2C

VEGFR2 conformation in the axitinib complex: X-ray crystallography. — Results: Crystal Structures Reveal Distinct JM Conformations; Figure 1A

VEGF-induced VEGFR2 phosphorylation in HUVECs

Cell-based study · Human umbilical vein endothelial cells (HUVECs), passage <6. [1]

Axitinib inhibited VEGF-induced VEGFR2 autophosphorylation in an ELISA concentration-response assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
VEGF-induced VEGFR2 autophosphorylationIC50 0.013 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
1:3 serial dilution; the tested concentration range is not specified in the inspected Cellular Assays section.
Exposure duration
1 h compound exposure followed by 5 min stimulation with 50 ng/mL rhVEGF.
Method
Cell-based concentration-response assay at 37°C; pVEGFR2 measured by ELISA.
Vehicle
0.1% DMSO in starvation medium.
Co-treatment
VEGF stimulation; no second therapeutic agent.
Reported limits
Table 1 provides no uncertainty estimate for this IC50; independent biological replicate count and tested concentration bounds are not specified in the inspected section.
Methods and source locations

Compound reported in the paper: Axitinib; Compound label in the paper: AG-013736

Compound-level published research; no batch equivalence or Adooq validation claimed.

Table 1, axitinib row, HUVEC pVEGFR2 column; Methods: Cellular Assays; Results: In Vitro Measurements

VEGF-induced VEGFR2 autophosphorylation: pVEGFR2 ELISA; duplicate concentrations at 1:3 serial dilution. VEGF-only positive control and unstimulated negative control. — Table 1: axitinib / HUVEC pVEGFR2; Methods: Cellular Assays

Axitinib In Vivo Studies

In PC-3 xenograft-bearing mice, oral axitinib at 25 mg/kg reduced tumor growth relative to vehicle, and combination with fractionated radiation produced greater suppression than either treatment alone. A separate PC-3/DU145 experiment found similar growth suppression when axitinib was given 1 h before or after radiation. These findings concern xenograft efficacy and treatment order, not pharmacokinetics or clinical benefit. [2]

PC-3 xenograft growth with axitinib and radiation

Animal study · PC-3 human prostate carcinoma xenografts in male NCr nu/nu mice. [2]

By day 10, axitinib alone and radiation alone each reduced tumor volume relative to vehicle controls. The combination produced smaller mean tumor volumes than either single treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume relative to vehicle and single-treatment groupsGroup comparison At day 10: each single treatment significantly below vehicle; combination significantly below single treatments.[2]

Conditions shared by the study groups

Route
Oral gavage
Treatment course
Two treatment weeks; Figure 1A follows tumor growth through day 11.
Vehicle
0.5% carboxymethylcellulose drug carrier.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Axitinib alone
25 mg/kg
Vehicle-only group; radiation-only comparator (2 Gy/fraction, 5 fractions/week).Tumor volume significantly lower than vehicle by day 10.[2]
Axitinib plus fractionated radiation
25 mg/kg
Vehicle-only group; radiation-only comparator (2 Gy/fraction, 5 fractions/week).Mean tumor volumes significantly smaller than either single-treatment group by day 10.[2]
Axitinib alone
Model: PC-3 xenografts in male NCr nu/nu mice.
Frequency: Daily on the treatment days marked in Figure 1A: days 0–4 and 7–11.
Reported limits: No exact numerical effect size extracted from the plotted curves.
Axitinib plus fractionated radiation
Model: PC-3 xenografts in male NCr nu/nu mice.
Frequency: Axitinib on Figure 1A treatment days, 1 h before each radiation fraction; radiation 2 Gy/fraction, 5 fractions/week.
Reported limits: No exact numerical effect size extracted from the plotted curves.
Methods and source locations

Compound reported in the paper: Axitinib; Compound label in the paper: AG-013736

Compound-level published research; no batch equivalence or Adooq validation claimed.

Methods: Tumor and Animal Models, Treatments, Statistical Analysis; Results: Tumor Progression is Significantly Inhibited; Figure 1A

Tumor volume relative to vehicle and single-treatment groups: Tumor-volume measurements three times weekly; Figure 1A reports means with SE for 7–12 tumors/group. Significance threshold P ≤ 0.05; exact comparison-specific P values not given here. — Results: Tumor Progression is Significantly Inhibited, first paragraph; Figure 1A caption; Statistical Analysis

Axitinib alone · Figure 1A and caption; Methods: Treatments; first Results paragraph

Axitinib plus fractionated radiation · Figure 1A and caption; Methods: Treatments; first Results paragraph

Daily axitinib–radiation order in prostate xenografts

Animal study · PC-3 and DU145 human prostate carcinoma xenografts in male NCr nu/nu mice. [2]

Giving axitinib 1 h before or 1 h after each radiation fraction produced nearly identical tumor-growth suppression in both models; the study did not establish an advantage for either order.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth for pre- versus post-irradiation axitinibSchedule comparison Nearly identical tumor-growth suppression with both schedules in PC-3 and DU145 models.[2]

Conditions shared by the study groups

Route
Oral gavage
Treatment course
Approximately 2 weeks.
Vehicle
0.5% carboxymethylcellulose drug carrier.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Axitinib before radiationVehicle control and the opposite treatment-order schedule.Tumor-growth suppression similar to the opposite treatment-order schedule in both models.[2]
Axitinib after radiationVehicle control and the opposite treatment-order schedule.Tumor-growth suppression similar to the opposite treatment-order schedule in both models.[2]
Axitinib before radiation
Model: PC-3 and DU145 human prostate carcinoma xenografts in male NCr nu/nu mice.
Frequency: Axitinib 1 h before each daily 2-Gy radiation fraction; radiation 5 days/week.
Reported limits: Axitinib dose not explicitly restated for Figure 3; no dose borrowed from Figure 1.
Axitinib after radiation
Model: PC-3 and DU145 human prostate carcinoma xenografts in male NCr nu/nu mice.
Frequency: Axitinib 1 h after each daily 2-Gy radiation fraction; radiation 5 days/week.
Reported limits: Axitinib dose not explicitly restated for Figure 3; no dose borrowed from Figure 1.
Methods and source locations

Compound reported in the paper: Axitinib; Compound label in the paper: AG-013736

Compound-level published research; no batch equivalence or Adooq validation claimed.

Methods: Treatments; Results: Altered Order of Treatment does not Modify Tumor Growth or Vessel Spacing; Figure 3A–B and caption

Tumor growth for pre- versus post-irradiation axitinib: Longitudinal tumor-volume comparison; 8–12 tumors/group; plotted means with SE. — Results: Altered Order of Treatment does not Modify Tumor Growth or Vessel Spacing, first paragraph; Figure 3A–B and caption

Axitinib before radiation · Methods: Treatments; Figure 3A–B and caption; Results: Altered Order of Treatment

Axitinib after radiation · Methods: Treatments; Figure 3A–B and caption; Results: Altered Order of Treatment

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 319460-85-0
Applications VEGFR inhibitor
Formula C22H18N4OS
Molecular Weight 386.5
Synonyms AG 013736
SMILES
CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 30 mg/mL (77.62 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Axitinib Research References

  1. [1] McTigue M, Murray BW, Chen JH, et al. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences of the United States of America (2012). PMID: 22988103 DOI: 10.1073/pnas.1207759109 Source material
  2. [2] Fenton BM, Paoni SF. Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiation research (2009). PMID: 19580496 DOI: 10.1667/rr1595.1 Source material

Publications

5 publications citing this product

  1. Sophie J. Bakri, .et al. , PLoS One, 2024, 19(6): e0304782 PMID: 38833447
  2. Hongwan Ding, .et al. , Toxicol Appl Pharmacol, 2024, May:486:116950 PMID: 38701902
  3. Hongwan Ding, .et al. , Research Square, 2023, Dec 28
  4. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  5. Youcef M. Rustum, .et al. , Int J Mol Sci, 2018, Nov; 19(11): 3378 PMID: 30380599

Added to your cart

View Cart Checkout
Loading...